Literature DB >> 27865545

Anti-CGRP antibodies block CGRP-induced diarrhea in mice.

Eric A Kaiser1, Brandon J Rea1, Adisa Kuburas1, Brian R Kovacevich2, Leon F Garcia-Martinez2, Ana Recober3, Andrew F Russo4.   

Abstract

The multifunctional neuropeptide calcitonin gene-related peptide (CGRP) and its receptor are expressed throughout the gastrointestinal tract. Previous studies have shown that CGRP has roles in intestinal motility, water secretion, and inflammation. Furthermore, animal studies have demonstrated CGRP involvement in diarrhea secondary to C. difficile and food allergies. Diarrhea thus provides a convenient bioassay of CGRP activity in the GI system. In this proof of principle study, we report that prophylactic administration of an anti-CGRP antibody is able to block CGRP-induced diarrhea in mice. As a control, the CGRP-receptor antagonist olcegepant also attenuated the diarrhea response to CGRP. This preclinical study indicates that anti-CGRP antibodies may provide a new preventative therapy for gastrointestinal disorders involving CGRP.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-CGRP antibody; CGRP; Colitis; Diarrhea; Mouse model; Olcegepant

Mesh:

Substances:

Year:  2016        PMID: 27865545      PMCID: PMC5429995          DOI: 10.1016/j.npep.2016.11.004

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  37 in total

1.  Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

Authors:  David W Dodick; Peter J Goadsby; Egilius L H Spierings; Joel C Scherer; Steven P Sweeney; David S Grayzel
Journal:  Lancet Neurol       Date:  2014-08-10       Impact factor: 44.182

2.  The novel CGRP receptor antagonist BIBN4096BS alleviates a postoperative intestinal inflammation and prevents postoperative ileus.

Authors:  T R Glowka; A Steinebach; K Stein; T Schwandt; M Lysson; B Holzmann; K Tsujikawa; W J de Jonge; J C Kalff; S Wehner
Journal:  Neurogastroenterol Motil       Date:  2015-04-30       Impact factor: 3.598

3.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Authors:  H Doods; G Hallermayer; D Wu; M Entzeroth; K Rudolf; W Engel; W Eberlein
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

4.  Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

Authors:  David W Dodick; Peter J Goadsby; Stephen D Silberstein; Richard B Lipton; Jes Olesen; Messoud Ashina; Kerri Wilks; David Kudrow; Robin Kroll; Bruce Kohrman; Robert Bargar; Joe Hirman; Jeff Smith
Journal:  Lancet Neurol       Date:  2014-10-05       Impact factor: 44.182

5.  Localization of calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) in human gastrointestinal tract.

Authors:  Graeme S Cottrell; Farzad Alemi; Jacob G Kirkland; Eileen F Grady; Carlos U Corvera; Aditi Bhargava
Journal:  Peptides       Date:  2012-03-30       Impact factor: 3.750

6.  Genetic enhancement of calcitonin gene-related Peptide-induced central sensitization to mechanical stimuli in mice.

Authors:  Blanca Marquez de Prado; Donna L Hammond; Andrew F Russo
Journal:  J Pain       Date:  2009-07-22       Impact factor: 5.820

7.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

8.  Comorbidity of headache and gastrointestinal complaints. The Head-HUNT Study.

Authors:  A H Aamodt; L J Stovner; K Hagen; J-A Zwart
Journal:  Cephalalgia       Date:  2008-02       Impact factor: 6.292

9.  Modulation of CGRP-induced light aversion in wild-type mice by a 5-HT(1B/D) agonist.

Authors:  Eric A Kaiser; Adisa Kuburas; Ana Recober; Andrew F Russo
Journal:  J Neurosci       Date:  2012-10-31       Impact factor: 6.167

10.  Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion.

Authors:  Zhongming Zhang; Christina S Winborn; Blanca Marquez de Prado; Andrew F Russo
Journal:  J Neurosci       Date:  2007-03-07       Impact factor: 6.167

View more
  11 in total

Review 1.  CGRP in Animal Models of Migraine.

Authors:  Anne-Sophie Wattiez; Mengya Wang; Andrew F Russo
Journal:  Handb Exp Pharmacol       Date:  2019

2.  The Influence of Inflammation and Nerve Damage on the Neurochemical Characterization of Calcitonin Gene-Related Peptide-Like Immunoreactive (CGRP-LI) Neurons in the Enteric Nervous System of the Porcine Descending Colon.

Authors:  Krystyna Makowska; Slawomir Gonkowski
Journal:  Int J Mol Sci       Date:  2018-02-12       Impact factor: 5.923

3.  FengLiao affects gut microbiota and the expression levels of Na+/H+ exchangers, aquaporins and acute phase proteins in mice with castor oil-induced diarrhea.

Authors:  Wenlu Chen; Xinyu Peng; Jingxian Yu; Xuanxuan Chen; Minggui Yuan; Rong Xiang; Limei He; Danni Yu; Huahua Kang; Yufang Pan; Zhihong Xu
Journal:  PLoS One       Date:  2020-07-28       Impact factor: 3.240

Review 4.  Mycotoxins and the Enteric Nervous System.

Authors:  Sławomir Gonkowski; Magdalena Gajęcka; Krystyna Makowska
Journal:  Toxins (Basel)       Date:  2020-07-19       Impact factor: 4.546

Review 5.  Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide's Motor-Stimulating and Prosecretory Function in the Intestine.

Authors:  Peter Holzer; Ulrike Holzer-Petsche
Journal:  Front Physiol       Date:  2022-01-11       Impact factor: 4.566

6.  Intranasal calcitonin gene-related peptide administration impairs fear memory retention in mice through the PKD/p-HDAC5/Npas4 pathway.

Authors:  Narumi Hashikawa-Hobara; Yoshikazu Yoneyama; Kyoushiro Fujiwara; Naoya Hashikawa
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.379

7.  Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: implications for migraine.

Authors:  Brandon J Rea; Anne-Sophie Wattiez; Jayme S Waite; William C Castonguay; Chantel M Schmidt; Aaron M Fairbanks; Bennett R Robertson; Cameron J Brown; Bianca N Mason; Maria-Cristina Moldovan-Loomis; Leon F Garcia-Martinez; Pieter Poolman; Johannes Ledolter; Randy H Kardon; Levi P Sowers; Andrew F Russo
Journal:  Pain       Date:  2018-11       Impact factor: 7.926

8.  The DH31/CGRP enteroendocrine peptide triggers intestinal contractions favoring the elimination of opportunistic bacteria.

Authors:  Olivia Benguettat; Rouba Jneid; Julie Soltys; Rihab Loudhaief; Alexandra Brun-Barale; Dani Osman; Armel Gallet
Journal:  PLoS Pathog       Date:  2018-09-04       Impact factor: 6.823

9.  Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.

Authors:  Mark E Bangs; David Kudrow; Shufang Wang; Tina M Oakes; Gisela M Terwindt; Delphine Magis; Laura Yunes-Medina; Virginia L Stauffer
Journal:  BMC Neurol       Date:  2020-01-17       Impact factor: 2.474

Review 10.  Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor.

Authors:  Andrew Blumenfeld; Paul L Durham; Alexander Feoktistov; Debbie L Hay; Andrew F Russo; Ira Turner
Journal:  Neurol Ther       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.